Annals of Surgical Oncology

, Volume 22, Supplement 3, pp 1164–1171 | Cite as

How Often Do Patients with Localized Melanoma Attend Follow-Up at a Specialist Center?

  • Niloofar Memari
  • Andrew Hayen
  • Katy J. L. Bell
  • Lucie Rychetnik
  • Rachael L. Morton
  • Kirsten McCaffery
  • John F. Thompson
  • Les Irwig
  • Robin M. TurnerEmail author



Post-treatment follow-up for patients with American Joint Committee on Cancer (AJCC) stage I/II melanoma is believed to be important for early detection of disease recurrence and new primary melanomas, but comes with costs to both patients and healthcare providers. We aimed to determine how frequently a cohort of patients attended follow-up after surgical treatment at one Specialist Center.


We used prospectively collected data from the Melanoma Institute Australia (MIA) for patients with AJCC stage I/II melanoma diagnosed between January 2008 and December 2011. The distribution of the number of recorded follow-up visits per patient was analyzed and compared with the number of follow-up visits recommended in the 2008 Australian and New Zealand Melanoma Management Guidelines.


A total of 3813 patients with stage I/II melanoma were identified. During the first year of follow-up post-surgery, 34 % of stage I patients and 14 % of stage II patients had the number of follow-up visits recommended in the guidelines. A large proportion of melanoma patients did not appear to be routinely followed up at MIA, with 43.2 % of stage I patients and 28.7 % of stage II patients having either no visit or only one visit post-surgery. During all years of follow-up, 13.2 % of stage I patients and 4.1 % of stage II patients had the number of follow-up visits at the specialist center as recommended in the guidelines.


The large proportion of patients who had fewer follow-up visits than expected suggests (i) many patients are followed up in clinics elsewhere, and/or (ii) post-surgical surveillance is less frequent in practice.


Melanoma Cutaneous Melanoma Specialist Center Primary Melanoma Shared Care 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Financial support for this study was provided entirely by an Australian National Health and Medical Research Council (NHMRC) Grant (633003) to the Screening and Test Evaluation Program. The funding agreement ensured the authors’ independence in designing the study, interpreting the data, and writing and publishing the report. The following authors are supported by the sponsor: Katy Bell is supported by an NHMRC Early Career Fellowship (1013390); Rachael Morton is funded by an NHMRC Early Career Researcher Fellowship (1054216); Kirsten McCaffery is funded by an NHMRC Career Development Fellowship (1029241).


Niloofar Memari, Andrew Hayen, Lucie Rychetnik, John F. Thompson, Les Irwig and Robin M. Turner have no conflicts of interest.


  1. 1.
    Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–2917.PubMedCrossRefGoogle Scholar
  2. 2.
    Erdmann F, Lortet-Tieulent J, Schuz J, et al. International trends in the incidence of malignant melanoma 1953-2008: are recent generations at higher or lower risk? Int J Cancer. 2013;132(2):385–400.PubMedCrossRefGoogle Scholar
  3. 3.
    Australian Institute of Health and Welfare & Australasian Association of Cancer Registries. Cancer in Australia: an overview, 2012. Cancer series no. 74. Cat. no. CAN 70 2012. Available at: Accessed 27 March 2014.
  4. 4.
    Francken AB, Shaw HM, Accortt NA, Soong SJ, Hoekstra HJ, Thompson JF. Detection of first relapse in cutaneous melanoma patients: implications for the formulation of evidence-based follow-up guidelines. Ann Surg Oncol. 2007;14(6):1924–1933.PubMedCrossRefGoogle Scholar
  5. 5.
    Francken AB, Bastiaannet E, Hoekstra HJ. Follow-up in patients with localised primary cutaneous melanoma. Lancet Oncol. 2005;6(8):608–621.PubMedCrossRefGoogle Scholar
  6. 6.
    Turner RM, Bell KJL, Morton RL, et al. Optimizing the frequency of follow-up visits for patients treated for localized primary cutaneous melanoma. J Clin Oncol. 2011;29(35):4641–4646.PubMedCrossRefGoogle Scholar
  7. 7.
    Rychetnik L, Morton RL, McCaffery K, Thompson JF, Menzies SW, Irwig L. Shared care in the follow-up of early-stage melanoma: a qualitative study of Australian melanoma clinicians’ perspectives and models of care. BMC Health Serv Res. 2012;12:468.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199–6206.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Australian National Health and Medical Research Council. Clinical practice guidelines for the management of melanoma in Australia and New Zealand. 2008. Available at: Accessed 19 March 2014.
  10. 10.
    Francken AB, Accortt NA, Shaw HM, et al. Follow-up schedules after treatment for malignant melanoma. Br J Surg. 2008;95(11):1401–1407.PubMedCrossRefGoogle Scholar
  11. 11.
    Rueth NM, Xing Y, Chiang YJ, et al. Is surveillance imaging effective for detecting surgically treatable recurrences in patients with melanoma? A comparative analysis of stage-specific surveillance strategies. Ann Surg. 2014;259(6):1215–1222.PubMedCrossRefGoogle Scholar
  12. 12.
    Holterhues C, van de Poll-Franse LV, de Vries E, Neumann HA, Nijsten TE. Melanoma patients receive more follow-up care than current guideline recommendations: a study of 546 patients from the general Dutch population. J Eur Acad Dermatol Venereol. 2012;26(11):1389–1395.PubMedCrossRefGoogle Scholar
  13. 13.
    Morton RL, Rychetnik L, McCaffery K, Thompson JF, Irwig L. Patients’ perspectives of long-term follow-up for localised cutaneous melanoma. Eur J Surg Oncol. 2013;39(3):297–303.PubMedCrossRefGoogle Scholar
  14. 14.
    Rychetnik L, McCaffery K, Morton RL, Thompson JF, Menzies SW, Irwig L. Follow-up of early stage melanoma: specialist clinician perspectives on the functions of follow-up and implications for extending follow-up intervals. J Surg Oncol. 2013;107(5):463–468.PubMedCrossRefGoogle Scholar
  15. 15.
    Rychetnik L, McCaffery K, Morton R, Irwig L. Psychosocial aspects of post-treatment follow-up for stage I/II melanoma: a systematic review of the literature. Psychooncology. 2013;22(4):721–736.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2015

Authors and Affiliations

  • Niloofar Memari
    • 1
  • Andrew Hayen
    • 2
  • Katy J. L. Bell
    • 1
    • 3
  • Lucie Rychetnik
    • 4
  • Rachael L. Morton
    • 1
    • 5
  • Kirsten McCaffery
    • 1
  • John F. Thompson
    • 6
    • 7
  • Les Irwig
    • 1
  • Robin M. Turner
    • 2
    Email author
  1. 1.School of Public HealthThe University of SydneySydneyAustralia
  2. 2.School of Public Health and Community MedicineUNSW AustraliaSydneyAustralia
  3. 3.Faculty of Health Sciences and MedicineBond UniversityGold CoastAustralia
  4. 4.School of MedicineUniversity of Notre Dame AustraliaSydneyAustralia
  5. 5.Health Economics Research Centre, Nuffield Department of Population HealthUniversity of OxfordOxfordUK
  6. 6.Melanoma Institute AustraliaSydneyAustralia
  7. 7.Sydney Medical SchoolThe University of SydneySydneyAustralia

Personalised recommendations